News | August 03, 2024
Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Both organisations enter into a long- term collaboration to expand patient access in India
Total transaction value of the divestment is Rs. 3,660 million
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Subscribe To Our Newsletter & Stay Updated
